Sophiris Announces First Patients Dosed in the “PLUS-1” Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

29-10-2013 Business Wire HealthComments (0)

Pharmaceutical

SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) today announced that enrollment has begun and the first patients have been dosed in a Phase 3 trial of PRX302 as a treatment for BPH.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top